Belgian biotechnology company ViroVet announced today that it has made its expertise, research staff as well as part of its research facility available to support COVID19 research and sample testing in Belgium.
According to its CEO, Dr Erwin Blomsma, the company has a clear moral obligation to divert some of its activities to join forces with the COVID19 teams to offer support where necessary.
Dr Nesya Goris, Chief Development Officer and co-founder of ViroVet added: "This is within our capability, our research team has the relevant expertise and training. As our company focuses on viral diseases, our laboratories and procedures are perfectly suitable, and we are ready to help."
The company confirms that it will continue with its outsourced studies on veterinary vaccines and antiviral drugs.
Notes to editors:
ViroVet develops antiviral drugs as well as plasmid launched live attenuated virus or PLLAV vaccines. For more information about the antiviral drugs or the PLLAV vaccine technology check out the video or visit our website.
For more information please contact Erwin Blomsma, CEO of ViroVet NV firstname.lastname@example.org Tel: +32 (0) 473 673550
About ViroVet NV
ViroVet is a biopharmaceutical company with a clear objective to develop innovative technologies to improve the health and value of livestock. The company is headquartered in Leuven (Heverlee), Belgium and has a pipeline of antiviral drugs and thermostable vaccines. ViroVet is one of the top-20 disruptors & innovators in animal health and was named start-up of the year 2015 and 2017 by Animal Pharm (part of the Business Intelligence Division of Informa PLC).
For more information about ViroVet see: www.virovet.com